Filed Jan 13, 2026Period of report Jan 13, 20260001437749-26-001170
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
PurchaseJan 13, 2026
common stockF1F2
33,333
$6.50
$216.66K
477,824
Direct
Filing footnotes · 6
F1The reporting person entered into a Securities Purchase Agreement with Clene Inc. and the other parties thereto, dated January 8, 2026, for the purchase of 33,333 shares of the Company's common stock, Series A Warrants to purchase 40,000 shares of the Company's common stock and Series B Warrants to purchase 93,333 shares of the Company's common stock, closing effective January 13, 2026.
F2The price of each Unit is $6.50 consisting of one share of Common Stock of Clene, one Series A Warrant and one Series B Warrant.
F3The exercise price of each Series A Warrant will increase from $6.00 to $7.00 per share if either: (a) the warrant is exercised prior to the Company's public announcement of the U.S. Food and Drug Administration's (the "FDA") posted action date under the Prescription Drug User Fee Act for the Company's new drug application ("NDA") for CNM-Au8 (the "Series A Trigger Announcement "); or (b) the volume-weighted average price (the "VWAP") of the Company's common stock equals or exceeds $10.00 on the measurement date associated with the Series A Trigger Announcement.
F4The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $6,684,000 by the applicable exercise price.
F5The exercise price for each Series B Warrant will increase from $6.00 to $12.50 per share if: (i) the Series B Warrant is exercised prior to the Company's public announcement of its receipt of written approval from the FDA of its NDA for CNM-Au8 in ALS or (ii) the VWAP of the Company's common stock is equal to or greater than $25.00 on the associated measurement date. The exercise price of the Series B Warrant will increase to $10.00 per share if the VWAP of the Company's common stock is equal to or greater than $20.00 on the associated measurement date.
F6The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $15,596,000 by the applicable exercise price.
Filed Dec 30, 2025Period of report Dec 23, 20250001835544-25-000005
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleDec 26, 2025
Common Stock
3,350
$6.32
$21.17K
795,824
IndirectBy Symbiosis II, LLC
SaleDec 24, 2025
Common Stock
1,490
$6.27
$9.34K
799,174
IndirectBy Symbiosis II, LLC
SaleDec 23, 2025
Common Stock
6,831
$6.27
$42.83K
800,664
IndirectBy Symbiosis II, LLC
Filing footnotes · 2
F1In connection with the cashless exercise of the pre-funded warrants, the issuer withheld shares of common stock to satisfy the $0.001 per-share exercise price, resulting in the issuance of fewer shares than the number of shares underlying the warrants exercised.
F2The pre-funded warrants are indefinite with no specified termination date.
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.